191 related articles for article (PubMed ID: 31074242)
1. A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.
Zhang Z; Huang H; Feng F; Wang J; Cheng N
J Gynecol Oncol; 2019 Jul; 30(4):e61. PubMed ID: 31074242
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Zhou H; Cao D; Yang J; Shen K; Lang J
Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
[TBL] [Abstract][Full Text] [Related]
3. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
[No Abstract] [Full Text] [Related]
4. Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases.
Chen J; Cao D
World J Surg Oncol; 2024 Jun; 22(1):169. PubMed ID: 38918837
[TBL] [Abstract][Full Text] [Related]
5. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.
Wang Y; Yu M; Yang JX; Cao DY; Yuan Z; Zhou HM; Zhang Y; Li L; Shen K; Wu H
Int J Clin Oncol; 2019 Jun; 24(6):712-720. PubMed ID: 30746595
[TBL] [Abstract][Full Text] [Related]
6. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer.
Gonthier C; Walker F; Luton D; Yazbeck C; Madelenat P; Koskas M
Gynecol Oncol; 2014 Apr; 133(1):33-7. PubMed ID: 24680589
[TBL] [Abstract][Full Text] [Related]
7. Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia.
Chen J; Cao D; Yang J; Yu M; Zhou H; Cheng N; Wang J; Zhang Y; Peng P; Shen K
Int J Gynecol Cancer; 2022 Dec; 32(12):1561-1567. PubMed ID: 36368706
[TBL] [Abstract][Full Text] [Related]
8. Aromatase Inhibition Ameliorates Decreased LH Output Found in Obese Women.
Jones K; Ryan S; Carlson NE; Chosich J; Bradford AP; Santoro N; Polotsky AJ
Reprod Sci; 2020 Apr; 27(4):1018-1023. PubMed ID: 32046430
[TBL] [Abstract][Full Text] [Related]
9. Effect of GnRH agonist and letrozole treatment in women with recurrent implantation failure.
Steiner N; Shrem G; Tannus S; Dahan SY; Balayla J; Volodarsky-Perel A; Tan SL; Dahan MH
Fertil Steril; 2019 Jul; 112(1):98-104. PubMed ID: 31133384
[TBL] [Abstract][Full Text] [Related]
10. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN].
Zhao LJ; Wei LH; Li XP; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):45-9. PubMed ID: 19563062
[TBL] [Abstract][Full Text] [Related]
11. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
He Y; Wang Y; Zhou R; Wang J
Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245
[TBL] [Abstract][Full Text] [Related]
12. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
13. Resolution of Uterine Arteriovenous Malformation and Maintenance of Reproduction in 20 Women Treated with a GnRH Agonist Concomitantly with an Aromatase Inhibitor and Tranexamic Acid.
Vilos AG; Oraif A; Machado M; Abu-Rafea B; Vilos GA
J Obstet Gynaecol Can; 2019 Jun; 41(6):772-781. PubMed ID: 30413336
[TBL] [Abstract][Full Text] [Related]
14. Mid-luteal phase gonadotropin-releasing hormone agonist support in frozen-thawed embryo transfers during artificial cycles: A prospective interventional pilot study.
Seikkula J; Ahinko K; Polo-Kantola P; Anttila L; Hurme S; Tinkanen H; Jokimaa V
J Gynecol Obstet Hum Reprod; 2018 Oct; 47(8):391-395. PubMed ID: 29684629
[TBL] [Abstract][Full Text] [Related]
15. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
[TBL] [Abstract][Full Text] [Related]
16. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
Pashov AI; Tskhay VB; Ionouchene SV
Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
[TBL] [Abstract][Full Text] [Related]
18. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
19. Management of recurrent implantation failure by gonadotropin-releasing hormone agonist and aromatase inhibitor suppression, in women without evidence of endometriosis.
Khayat S; Elliott B; Dahan MH
Gynecol Endocrinol; 2019 Mar; 35(3):267-270. PubMed ID: 30328740
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.
Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F
J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
